

# Curriculum Vitae

Dr. Simon Frey

---

## Research & Teaching

- Assessment of health care resource utilization using administrative data
- Econometrics, decision modelling, outcomes research, evaluation of health technologies
- Tutorials in "Empirical Social Science Research Methods" (MSc), "Health Economic Evaluation" (MSc), "Decision Theory" (MSc) BSc- and MSc-Seminars

## Education

2010–2015	Doctor of Business and Economics, Faculty of Business Administration, University of Hamburg, Hamburg, Germany
2005–2010	Diploma (equivalent to Master's degree) in Health Economics, University of Cologne, Cologne, Germany
2008	Economics & Business Administration, Copenhagen Business School, Copenhagen, Denmark

## Professional Experience

06/2016–date	Head of junior research group / Hamburg Center for Health Economics (HCHE), University of Hamburg, Hamburg, Germany
08/10–05/2016	Research associate / Hamburg Center for Health Economics (HCHE), University of Hamburg, Hamburg, Germany
03/10–07/10	Intern / Department of Health Economics and Health Care Management, Helmholtz Zentrum Muenchen, Munich, Germany
03/09–11/09	Intern / Corporate Affairs & Business Support department, GlaxoSmithKline, Munich, Germany
04/08–07/08	Intern / Division of Country Health Systems at the World Health Organization, Copenhagen, Denmark
08/07–10/07	Intern / M&A-Advisory department, PricewaterhouseCoopers Corporate Finance, Frankfurt/Main, Germany

## Memberships & Organisations

Member of the executive board, Hamburg Business School, University of Hamburg

German Health Economics Association (dggoe)

International Health Economics Association (iHEA)

International Society For Pharmacoeconomics and Outcomes Research (ISPOR)

## Conference Proceedings

07/2016	1 <sup>st</sup> EuHEA conference (formerly: European Conference on Health Economics)
03/2015	7th Annual meeting of the German Health Economics Association, Bielefeld
07/2014	10th European Conference on Health Economics (ECHE), Dublin, Ireland
03/2014	6th Annual meeting of the German Health Economics Association, Munich, Germany
11/2012	15th Annual European Congress, International Society for Pharmacoeconomics and Outcomes Research (ISPOR), Berlin, Germany
07/2012	9th European Conference on Health Economics (ECHE), Zurich, Switzerland
03/2012	4th Annual meeting of the German Health Economics Association, Konstanz, Germany
11/2011	14th Annual European Congress, International Society for Pharmacoeconomics and Outcomes Research (ISPOR), Madrid, Spain
07/2011	8th World Congress on Health Economics, International Health Economics Association (iHEA), Toronto, Canada
03/2011	3rd Annual meeting of the German Health Economics Association, Bayreuth, Germany

## Peer-reviewed publications

2016	<b>Frey S</b> , Blankart CR, & Stargardt T, 2016. Economic Burden and Quality-of-Life Effects of Chronic Lymphocytic Leukemia: A Systematic Review of the Literature. <i>PharmacoEconomics</i> , 34(5), 479–498. [IF 2.450] <a href="#">8 Link</a>
2016	Müller D, Gerber-Grote A, Stollenwerk B, Stock S, Auweiler PWP, <b>Frey S</b> , ... Hellmich M, 2016. Reporting health care decision models: a prospective reliability study of a multidimensional evaluation framework. <i>Expert Review of Pharmacoeconomics &amp; Outcomes Research</i> , 16(5), 619–627. <a href="#">8 Link</a> [IF 1.669]
2015	Achelrod D, Wenzel U & <b>Frey S</b> , 2015. Systematic Review and Meta-Analysis of the Prevalence of Resistant Hypertension in Treated Hypertensive Populations. <i>American Journal of Hypertension</i> , 28(3), 355–361. [IF 3.402] <a href="#">8 Link</a>
2014	<b>Frey S</b> , 2014. The economic burden of schizophrenia in Germany: A population-based retrospective cohort study using genetic matching. <i>European Psychiatry</i> , 29(8), 479–489. [IF 3.285] <a href="#">8 Link</a>
2014	<b>Frey S</b> , Linder R, Juckel G, Stargardt T, 2014. Cost-effectiveness of long-acting injectable risperidone versus flupentixol decanoate in the treatment of schizophrenia – a Markov model parameterized using administrative data. <i>The European Journal of Health Economics</i> , 15(2):133–142. [IF 2.095] <a href="#">8 Link</a>
2012	<b>Frey S</b> , Stargardt T, 2012. Performance of Compliance and Persistence Measures in Predicting Clinical and Economic Outcomes Using Administrative Data from German Sickness Funds. <i>Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy</i> , 32(10):880–889. [IF 2.311] <a href="#">8 Link</a>
2009	Bufe A, <b>Frey S</b> , Briswalter S, 2009. Costs Caused by Bleeds within the Therapy of Acute Coronary Syndromes in Germany [German]. <i>Herz</i> , 34(6):479–484. [IF 0.894] <a href="#">8 Link</a>

## Non peer-reviewed publications

2013	<b>Frey S</b> , Schreyögg J, 2013. Lexikon Gesundheitsökonomie: Markov-Modellierung [German]. <i>Gesundheitsökonomie &amp; Qualitätsmanagement</i> , 18(2): 64.
------	---